Pregnancy Related Clinical Trial
— BETTEROfficial title:
A Randomized Control Trial to Improve Metabolic Outcomes in African American Pregnant Women
The purpose of this randomized controlled trial is to establish the effectiveness of a culturally targeted and individually tailored behavioral intervention to promote maternal glucose metabolism in African American women.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 30, 2026 |
Est. primary completion date | November 30, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - African American pregnant woman. - Women between 16 and 22 GWs. - Overweight or obese - pregravid Body Mass Index >25.0 kg/m2. - Singleton gestation. - Established prenatal care at The University of Illinois Hospital & Health Sciences. - System Obstetric (UIHHSS' OB) clinics. Able to understand, speak and write in English. Exclusion Criteria: - Multiple gestations. - Night-shift work. - Diagnosed sleep disorders. - Known fetal chromosomal or anatomical abnormalities. - Diagnosed mood disorders. - Gestational diabetes in early pregnancy. - Glycated Hemoglobin (HbA1c) = 6.5%. - Hypoglycemic medications. - Stimulant medication or taking a sleeping aid. - Active drug abuse/excessive alcohol intake. |
Country | Name | City | State |
---|---|---|---|
United States | University of Illinois at Chicago | Chicago | Illinois |
United States | University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | National Institute on Minority Health and Health Disparities (NIMHD), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fasting Glucose at baseline | A fasting blood sample for glucose will be collected | 16-22 Gestational Weeks (GWs) | |
Primary | Fasting Glucose | A fasting blood sample for glucose will be collected | 28-32 Gestational Weeks (GWs) | |
Secondary | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at baseline | Insulin Resistance | 16-22 Gestational Weeks | |
Secondary | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Insulin Resistance | 28-32 Gestational Weeks | |
Secondary | Glucose Area Under the Curve at baseline | Glucose tolerance | 16-22 Gestational Weeks | |
Secondary | Glucose Area Under the Curve | Glucose tolerance | 28-32 Gestational Weeks | |
Secondary | Glucose Area Under the Curve | Glucose tolerance | 34-36 Gestational Weeks | |
Secondary | Sleep Quality - Self-reported of sleep quality at the baseline "before the intervention" | Self-reported sleep quality over the past month will be assessed by using Pittsburgh Sleep Quality Index (PSQI) Questionnaire.
It is a 19 self-rated questions, 4-point Likert-scale. Each score ranges from 0 - 3. It is a self-report measure that assesses sleep quality and severity of specific sleep related complaints over the previous month. Higher score=poorer sleep quality. |
16-22 Gestational Weeks | |
Secondary | Sleep Quality - Self-reported of sleep quality | Self-reported sleep quality over the past month will be assessed by using Pittsburgh Sleep Quality Index (PSQI) Questionnaire.
It is a 19 self-rated questions, 4-point Likert-scale. Each score ranges from 0 - 3. It is a self-report measure that assesses sleep quality and severity of specific sleep related complaints over the previous month. Higher score=poorer sleep quality. |
28-32 Gestational Weeks | |
Secondary | Sleep Quality - Self-reported of sleep quality | Self-reported sleep quality over the past month will be assessed by using Pittsburgh Sleep Quality Index (PSQI) Questionnaire.
It is a 19 self-rated questions, 4-point Likert-scale. Each score ranges from 0 - 3. It is a self-report measure that assesses sleep quality and severity of specific sleep related complaints over the previous month. Higher score=poorer sleep quality. |
34-36 Gestational Weeks | |
Secondary | Sleep duration and sleep timing - Subjectively and Objectively Assessment at the baseline "before the intervention" | sleep duration will be assessed using a wearable device (Fitbit Charge 4) accompanied by a sleep diary.
Sleep timing (midpoint) will be calculated as the halfway point between bedtime and rise time. |
16-22 Gestational Weeks | |
Secondary | Sleep duration and sleep timing - Subjective and Objective Assessment | sleep duration will be assessed using a wearable device (Fitbit Charge 4) accompanied by a sleep diary.
Sleep timing (midpoint) will be calculated as the halfway point between bedtime and rise time. |
28-32 Gestational Weeks | |
Secondary | Sleep duration and sleep timing - Subjective and Objective Assessment | Sleep duration will be assessed using a wearable device (Fitbit Charge 4) accompanied by a sleep diary. Sleep timing (midpoint) will be calculated as the halfway point between bedtime and rise time. | 34-36 Gestational Weeks | |
Secondary | Medical Records Extraction Form | Maternal-fetal outcomes will be assesses by reviewing participants' medical records and report the incidence of: newborn's hypoglycemia, macrosomia, & intensive care admission - preterm and cesarean deliveries, preeclampsia, gestational hypertension and any other important events.
In addition, Apgar scores and birth weight will be reported. Pregnancy outcomes will be obtained from medical charts to understand if there are differences regarding these outcomes between the BETTER and control groups. |
"post delivery, up to 3 months post intervention" |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT06258902 -
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
|
||
Completed |
NCT05487196 -
Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
|
Phase 2 | |
Completed |
NCT03750968 -
Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
|
Phase 2 | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Completed |
NCT04296396 -
Opioid Prescription After Cesarean Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069869 -
Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069856 -
Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Not yet recruiting |
NCT06079918 -
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
|
Phase 3 |